Fixed pricing for an unlimited number of timepoints per patient over the course of a study. The Tracer assay works with blood and urine samples.
Per volume sensitivity and specificity best in the industry. Effective at lower blood volumes than conventional NGS-based ctDNA assays.
Leverage existing biomarker data for initial tumor-informed assay design and validation. Sub 7-day turnaround for subsequent samples.
Supports continuous monitoring of the patient's molecular response over an extended period, enabling scientists and clinicians to track changes in real-time. Overlay radiomics and other temporal data through visual dashboards.
Accurately quantifies molecular response and changes in tumor fraction over time through the integration of longitudinal timepoints.
Each Tracer personalized assay is designed from tumor-derived variants excluding non-cancerous CHIP alterations.
Tracer detects minute changes in Tumor Fraction and very low levels of residual disease, as low as 10 ppm.
The Tracer assay detects ctDNA in Blood and Urine.
Conventional (NGS) blood-based ctDNA assays require large sample volumes and have high failure rates. Tracer has significantly lower volume requirements.
Tracer can leverage existing biomarker data for initial tumor-informed assay design and validation. Sub 7 day turnaround for subsequent samples.
Prior to co-founding Tracer Biotechnologies Mark was the CEO and co-founder of SolveBio (acquired by Precision Medicine Group). Mark received his PhD in Genetics from Stanford University and AB in Biochemistry and Computer Science from Harvard University.
Gopal is the co-founder and CSO of Tracer Biotechnologies. Previously he served as CTO of Wellframe (acquired by Blackstone). Gopal completed his postdoctoral work at the Broad Institute and received his PhD in Mathematics from MIT and MD from Harvard Medical School.
Dr. Alex Parker has broad experience as a board member, advisor, and executive at pivotal genomics and early detection ventures. Among other roles, Alex served as VP of Business Development at Foundation Medicine, SVP of Clinical Product Strategy at Thrive Earlier Detection Corp, and Board Member of C2i Genomics. Currently, Alex serves on the board of several companies in the genomics and pathology space and is a Strategic Advisor to Earli, inc., Mursla Bio, Casdin Capital, and Tracer Biotechnologies.
Dr. Barrett served as the SVP of Translational Medicine, Oncology at AstraZeneca and VP and Global Head of Biomarkers and Imaging at Novartis. Currently, Dr. Barrett serves as the Chief Scientific Officer of Precede Biosciences.
Dr. Eliezer (Eli) Van Allen is an Associate Professor of Medicine at Harvard Medical School, Chief of the Division of Population Sciences at the Dana-Farber Cancer Institute, an Institute Member at the Broad Institute of MIT and Harvard, and a Member Researcher in The Parker Institute for Cancer Immunotherapy at Dana-Farber Cancer Institute.
Dr. Jacob Berchuck is a board-certified Medical Oncologist and Assistant Professor of Medical Oncology at the Winship Cancer Institute of Emory University. Previously, Dr. Berchuck served as an Assistant Professor of Medicine at Harvard Medical School and a Medical Oncologist at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital. Dr. Berchuck leads a translational research lab focused on using novel liquid tools to develop circulating biomarkers to guide treatment decisions and decipher mechanisms of therapeutic resistance.
Prior to advising Tracer on IP Strategy, Bill was a law firm partner and senior executive of publicly traded companies, including Guardant Health and Fluidigm. Bill advises biotech start-ups on intellectual property matters, including building comprehensive patent portfolios, as well as implementing offensive and defensive patent strategies on a worldwide basis.
